Transcriptomics, beyond genomics and beneath proteomics provide us with precious information on geneexpression and have promising clinical applications. In their recent paper Kelley Nunez et al. from Ochsner Health in New Orleans present one of them that, through a better understanding of the effect of liver directed therapies on early-stage hepatocellular carcinoma could help identify therapeutic targets to promote complete pathologic necrosis and improve recurrence-free survival after liver transplantation. 

We at Lifency congratulate the authors on this extremely interesting paper and gladly support – through our scientific communication activities – lifesciences and medical progress

Learn more (Free PMC article) on:
Núñez KG, Sandow T, Lakey MA, Fort D, Cohen AJ, Thevenot PT. Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy. Front Oncol. 2022 Jun 17;12:809860. doi: 10.3389/fonc.2022.809860. PMID: 35785174; PMCID: PMC9248864.